Risk factors for drug-induced liver disease

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Variables that predispose individuals to develop idiosyncratic drug-induced liver injury (DILI) can be categorized into genetic and nongenetic risk factors. Nongenetic risk factors, which are the subject of this chapter, can be broadly categorized into host-related factors, environmental factors, and compound characteristics. Various host factors such as age, gender, and pregnancy; comorbidities such as obesity, diabetes, and underlying liver disease; and underlying nutritional status are associated with increased risk of liver injury due to selected compounds, rather than all-cause DILI. Environmental factors such as alcohol consumption may be associated with increased risk from specific compounds such as halothane, isoniazid, methotrexate, and highly active antiretroviral therapy. Although smoking has demonstrable effects on various drug-metabolizing enzymes, there is no evidence to suggest that smoking is associated with increased susceptibility to DILI in humans. Various compound characteristics such as daily dose, drug interactions, metabolic profile, and polypharmacy have been explored as risk factors for DILI in humans, but their overall impact on the risk to develop DILI appears rather modest.

Original languageEnglish
Title of host publicationDrug-Induced Liver Disease
PublisherElsevier Inc.
Pages265-274
Number of pages10
ISBN (Print)9780123878175
DOIs
StatePublished - 2013

Fingerprint

Chemical and Drug Induced Liver Injury
Smoking
Polypharmacy
Metabolome
Isoniazid
Highly Active Antiretroviral Therapy
Halothane
Nutritional Status
Drug Interactions
Methotrexate
Alcohol Drinking
Comorbidity
Liver Diseases
Obesity
Pregnancy
Liver
Wounds and Injuries
Enzymes
Pharmaceutical Preparations

Keywords

  • Alcohol consumption
  • Daily dose
  • Drug-induced liver injury
  • Polypharmacy
  • Risk factors

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Risk factors for drug-induced liver disease. / Vuppalanchi, Raj; Chalasani, Naga.

Drug-Induced Liver Disease. Elsevier Inc., 2013. p. 265-274.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vuppalanchi, Raj ; Chalasani, Naga. / Risk factors for drug-induced liver disease. Drug-Induced Liver Disease. Elsevier Inc., 2013. pp. 265-274
@inbook{befcfdeeb8b545bfb7758ce44b58a45c,
title = "Risk factors for drug-induced liver disease",
abstract = "Variables that predispose individuals to develop idiosyncratic drug-induced liver injury (DILI) can be categorized into genetic and nongenetic risk factors. Nongenetic risk factors, which are the subject of this chapter, can be broadly categorized into host-related factors, environmental factors, and compound characteristics. Various host factors such as age, gender, and pregnancy; comorbidities such as obesity, diabetes, and underlying liver disease; and underlying nutritional status are associated with increased risk of liver injury due to selected compounds, rather than all-cause DILI. Environmental factors such as alcohol consumption may be associated with increased risk from specific compounds such as halothane, isoniazid, methotrexate, and highly active antiretroviral therapy. Although smoking has demonstrable effects on various drug-metabolizing enzymes, there is no evidence to suggest that smoking is associated with increased susceptibility to DILI in humans. Various compound characteristics such as daily dose, drug interactions, metabolic profile, and polypharmacy have been explored as risk factors for DILI in humans, but their overall impact on the risk to develop DILI appears rather modest.",
keywords = "Alcohol consumption, Daily dose, Drug-induced liver injury, Polypharmacy, Risk factors",
author = "Raj Vuppalanchi and Naga Chalasani",
year = "2013",
doi = "10.1016/B978-0-12-387817-5.00016-9",
language = "English",
isbn = "9780123878175",
pages = "265--274",
booktitle = "Drug-Induced Liver Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Risk factors for drug-induced liver disease

AU - Vuppalanchi, Raj

AU - Chalasani, Naga

PY - 2013

Y1 - 2013

N2 - Variables that predispose individuals to develop idiosyncratic drug-induced liver injury (DILI) can be categorized into genetic and nongenetic risk factors. Nongenetic risk factors, which are the subject of this chapter, can be broadly categorized into host-related factors, environmental factors, and compound characteristics. Various host factors such as age, gender, and pregnancy; comorbidities such as obesity, diabetes, and underlying liver disease; and underlying nutritional status are associated with increased risk of liver injury due to selected compounds, rather than all-cause DILI. Environmental factors such as alcohol consumption may be associated with increased risk from specific compounds such as halothane, isoniazid, methotrexate, and highly active antiretroviral therapy. Although smoking has demonstrable effects on various drug-metabolizing enzymes, there is no evidence to suggest that smoking is associated with increased susceptibility to DILI in humans. Various compound characteristics such as daily dose, drug interactions, metabolic profile, and polypharmacy have been explored as risk factors for DILI in humans, but their overall impact on the risk to develop DILI appears rather modest.

AB - Variables that predispose individuals to develop idiosyncratic drug-induced liver injury (DILI) can be categorized into genetic and nongenetic risk factors. Nongenetic risk factors, which are the subject of this chapter, can be broadly categorized into host-related factors, environmental factors, and compound characteristics. Various host factors such as age, gender, and pregnancy; comorbidities such as obesity, diabetes, and underlying liver disease; and underlying nutritional status are associated with increased risk of liver injury due to selected compounds, rather than all-cause DILI. Environmental factors such as alcohol consumption may be associated with increased risk from specific compounds such as halothane, isoniazid, methotrexate, and highly active antiretroviral therapy. Although smoking has demonstrable effects on various drug-metabolizing enzymes, there is no evidence to suggest that smoking is associated with increased susceptibility to DILI in humans. Various compound characteristics such as daily dose, drug interactions, metabolic profile, and polypharmacy have been explored as risk factors for DILI in humans, but their overall impact on the risk to develop DILI appears rather modest.

KW - Alcohol consumption

KW - Daily dose

KW - Drug-induced liver injury

KW - Polypharmacy

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84882690687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882690687&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-387817-5.00016-9

DO - 10.1016/B978-0-12-387817-5.00016-9

M3 - Chapter

AN - SCOPUS:84882690687

SN - 9780123878175

SP - 265

EP - 274

BT - Drug-Induced Liver Disease

PB - Elsevier Inc.

ER -